Dr. Hou Ming: BTK Inhibitor Ibrutinib Offer Limitless Prospects for ITP Treatment

Dr. Hou Ming: BTK Inhibitor Ibrutinib Offer Limitless Prospects for ITP Treatment

Editor's Note: From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) Congress was held in Frankfurt, Germany. During this conference, Dr. Hou Ming's team at Qilu Hospital, Shandong University, China, presented the research findings on the use of the BTK inhibitor ibrutinib for primary immune thrombocytopenia (ITP) (abstract S299). To gain deeper insights into this study and its implications for the current status of ITP treatment, Oncology Frontier had an exclusive interview with Dr. Hou Ming. He provided a detailed overview of the current situation of ITP treatment in China and the promising future of using BTK inhibitors for ITP therapy.
Dr. Taisheng Li: A New Concept in Comprehensive Diagnosis and Treatment in the Post-ART Era of HIV/AIDS

Dr. Taisheng Li: A New Concept in Comprehensive Diagnosis and Treatment in the Post-ART Era of HIV/AIDS

Editor's Note: The 15th National Conference on AIDS and Hepatitis C, hosted by the Chinese Medical Association and its Infectious Diseases Branch, took place in Guangzhou from November 10 to 12, 2023. Dr. Taisheng Li, the conference chair and a renowned figure from Peking Union Medical College Hospital, delivered a captivating presentation titled "A New Concept in Comprehensive Diagnosis and Treatment in the Post-ART Era of HIV/AIDS." In an exclusive interview with Infectious Disease Frontline, he further shared insights on topics including immune reconstitution deficiency in HIV-infected individuals.
Examining LLDT-8’s Potential for Suppressing Immune Activation in SIV/HIV Infection: A Transcriptomic study in Rhesus Macaques

Examining LLDT-8’s Potential for Suppressing Immune Activation in SIV/HIV Infection: A Transcriptomic study in Rhesus Macaques

Human Immunodeficiency Virus (HIV) infection remains a global health challenge, with chronic immune activation playing a pivotal role in disease progression. While antiretroviral therapy (ART) has significantly improved the prognosis by suppressing viral replication, persistent immune activation continues to undermine immune function. LLDT-8, an optimized analog of triptolide, has emerged as a potential immunomodulatory agent, exhibiting promising results in preclinical studies. This article explores in detail the comprehensive transcriptomic analysis conducted to unravel the immunomodulatory effects of LLDT-8 in simian immunodeficiency virus (SIV)-infected rhesus macaques. The study involved a combination of LLDT-8 treatment and ART, employing flow cytometry and RNA-seq analyses to investigate the treatment effects.